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is	 a	 lack	of	 efficacy	of	 antihistamines	 in	 controlling	 its	 symptoms,	which	prevents	
their clinical application. We have reported that antihistamines potentiate glucocor‐
ticoids’	responses	in	vitro	and	recent	observations	have	indicated	that	the	coadmin‐
istration of an antihistamine and a synthetic glucocorticoid has synergistic effects 
on	a	murine	model	of	allergic	rhinitis.	Here,	the	aim	of	this	work	is	to	establish	if	this	
therapeutic combination could be beneficial in a murine model of asthma. We used 
an	allergen‐induced	model	of	asthma	(employing	ovalbumin)	to	evaluate	the	effects	
of	 the	 synthetic	 glucocorticoid	 dexamethasone	 combined	 with	 the	 antihistamine	
azelastine.	Our	results	indicate	that	the	cotreatment	with	azelastine	and	a	suboptimal	
dose	of	dexamethasone	can	 improve	allergic	 lung	 inflammation	as	shown	by	a	de‐
crease	in	eosinophils	in	bronchoalveolar	lavage,	fewer	peribronchial	and	perivascular	




to achieve a therapeutic effect. These findings provide first new insights into the 
potential benefits of glucocorticoids and antihistamines combination for the treat‐
ment of asthma and grants further research to evaluate this approach in other related 
inflammatory conditions.
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1  | INTRODUC TION
Over	300	million	people	worldwide	suffer	from	asthma	and	it	is	ex‐
pected that 100 million more will do it in the year 2025.1	Asthma	
prevalence	is	variable	and	growing	in	the	last	decades,	ranking	be‐
tween 2% and 10%.2 It is also an important global issue due to its 
morbidity	and	mortality.	Asthma	is	the	cause	of	1	in	every	250	global	
deaths and it is associated with an estimated loss of 15 million years 
of	productive	life	per	year	(measured	as	disability‐adjusted	life	years	
or	DALYs).3
We	 have	 previously	 reported	 that	 antihistamines,	 acting	 on	
the	histamine	H1	receptor,	are	capable	of	enhancing	the	transcrip‐
tional	activity	of	the	glucocorticoid	receptor	(GR),4 an effect that 
could	have	clinical	 relevance,	particularly	 for	 inflammation‐asso‐
ciated	 conditions.	 Importantly,	 the	 GR	 and	 the	 H1 receptor are 
the targets of the largest number of drugs currently approved for 
clinical treatment.5 The combination of a synthetic glucocorticoid 
and an antihistamine is commonly administered in allergic rhinitis 
and atopic dermatitis.6,7	Furthermore,	coadministration	of	the	an‐
tihistamine	 azelastine	 and	 the	 synthetic	 glucocorticoid	mometa‐
sone synergistically ameliorated allergic inflammation in a murine 
model of allergic rhinitis.8	 Therefore,	 coadministration	 therapies	
could lead to the design of new strategies to treat inflamma‐
tion‐associated	diseases.	In	this	sense,	asthma	is	an	inflammatory	
disease	 that	 represents	 an	 interesting	 experimental	 scenario	 to	
extend	this	concept.
Glucocorticoids	 (GCs)	 are	 among	 the	 most	 effective	 current	
therapy for asthma.9	However,	the	existence	of	 important	adverse	
effects as well as asthmatics patients unable to control symptoms 
generates the need of new therapeutic strategies.10	Histamine	has	
been	consistently	related	to	the	development	of	the	disease,	since	
its	 identification	as	a	potent	constrictor	of	 the	smooth‐muscle	air‐
way and its increased presence in diseased tissue.11	Histamine	lev‐





asthma is an enigma. Despite the abundance of preclinical informa‐
tion	endorsing	histamine's	role	in	asthma,	there	is	a	lack	of	efficacy	
of antihistamines in controlling its symptoms. Several clinical stud‐
ies have shown that antihistamines were unable to control some of 
asthma	symptoms	in	adults	at	regular	doses,13 while an improvement 
of the symptoms was observed at higher doses.14
Based	on	previous	observations	 in	vitro	 4	and	 in	vivo,8 we hy‐
pothesized	that	the	enhancement	of	GR	transcriptional	activity	by	
antihistamines	could	be	used	 to	 reduce	GC’s	effective	doses	used	
to	 counteract	 asthma	 symptoms,	 possibly	 resulting	 in	 new	 (and	
safer)	 therapeutic	strategies	 to	 treat	asthma.	To	 this	aim,	we	used	
an	 allergen‐induced	murine	model	 of	 asthma,	 as	 it	 represents	 the	
most	prevalent	form	of	asthma	(allergic	asthma),	ideal	to	study	the	








conditions that could be linked to asthma.16‐19
Our	 results	 show	 that	AZE	 potentiates	DEX‐induced	GR	 tran‐
scriptional	activity	in	vivo,	and	that	the	combination	of	both	drugs	
results	in	a	reduction	of	the	effective	GC	concentration	needed	to	
achieve	 a	 therapeutic	 effect	 in	 an	 allergen‐induced	murine	model	
of asthma. These findings provide insight into the potential benefits 
of	GCs	and	antihistamines	combination	for	the	treatment	of	asthma	
symptoms and grant further research to evaluate this approach for 
the treatment of other inflammatory conditions.




Sigma	 Chemical	 Company.	 Fetal	 calf	 serum	 (FCS)	 was	 purchased	
from	Natocor	(Córdoba,	Argentina).	All	other	chemicals	were	of	ana‐








T‐antigen)	 cells	 were	 obtained	 from	 the	 American	 Type	 Culture	
Collection	(ATCC:	Manassas,	VA,	USA)	and	cultured	in	DMEM	sup‐
plemented	with	10%	fetal	calf	serum	and	5‐μg/mL	gentamicin.	Cells	




2.4 | Transfection and reporter gene assays
HEK293T	cells	seeded	on	24‐well	plates	were	cotransfected	with	
the	 pRSV‐GR,	 pCEFL‐H1	 receptor,	 and	 the	 luciferase	 reporter	
plasmids	TAT3‐Luc	or	 IL6‐Luc	using	 the	K2	Transfection	System	
(Biontex,	Munich,	Germany)	 according	 to	 the	manufacturer's	 in‐
structions.	 After	 4	 hours,	 cells	 were	 seeded	 in	 96‐well	 plates,	
and	 24	 hours	 later	 were	 starved	 overnight	 and	 then	 stimulated	
with	 ligands.	 After	 a	 kinetic	 assessment,	 luciferase	 activity	 was	
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measured	 at	 the	 optimal	 time	 of	 24	 hours	 using	 the	 Steady‐Glo	
Luciferase	 Assay	 System	 according	 to	 the	 manufacturer's	 in‐













Argentina)	and	maintained	 in	our	animal	 facilities	 for	use	 through‐







2.6 | Development of the experimental protocol
Thirty	animals	with	an	average	weight	of	20	gr	were	randomized	and	











One	 hour	 after	 the	 last	 exposure,	 mice	 were	 intranasally	 treated	
with	7	μL	of	a	water	solution	containing	the	different	drugs.	The	ex‐
perimental	protocol	is	summarized	as	follows:
To	 perform	 the	 experiment,	 30	 animals	 were	 randomized	 and	 
divided	into	six	different	experimental	groups	as	follows:
1.	 Naïve	group	(N):	negative	control	of	the	disease	model.	Animals	
not	 sensitized	 with	 OVA,	 only	 injected	 and	 airway	 challenged	
with	 PBS.
2.	 Asthmatic	 group	 (OVA):	 positive	 control	 of	 the	 disease	 model.	
Animals	sensitized	with	OVA	and	intranasally	treated	with	PBS.
3.	 Optimal	 dose	 of	 dexamethasone	 group	 (OD):	 positive	 control	
of	 the	 treatment.	Animals	 sensitized	with	OVA	and	 intranasally	
treated	with	 a	DEX	 solution	 in	 a	 dose	 corresponding	 to	 1	mg/
kg.25‐27	 This	 dose	 equals	 to	 1.2	mg	of	 inhaled	 corticosteroid	 in	
humans,28‐30 in the order of recommended dose for the control of 
asthma	symptoms	according	to	GINA.31






corresponding to 0.5 mg/kg.
6.	 Cotreatment	of	 suboptimal	dose	of	dexamethasone	and	azelas‐




It has been described that the allergen and the adjuvant in this partic‐
ular	strain	promotes	an	antigen‐specific	Th2	immune	response,	involv‐






Animals	 were	 euthanized	 with	 isoflurane.	 The	 chest	 wall	 was	
opened,	and	the	animals	were	exsanguinated	by	cardiac	puncture.	
Serum	was	prepared	 and	 stored	 at	 −20°C.	 The	 trachea	was	 can‐
nulated	 after	 blood	 collection.	Bronchoalveolar	 lavage	 (BAL)	was	
performed	 four	 times	with	1	mL	of	 sterile	PBS.	 Lavage	 fluid	was	
collected,	centrifuged	at	300g	for	10	min,	and	the	pellet	was	resus‐
pended	in	0.5‐mL	PBS.	BAL	differential	cell	counts	were	performed	
on cytocentrifuge slides prepared by centrifugation of samples 
at 300g	for	5	min	(Cytospin	4;	Shandon,	Pittsburg,	PA,	USA).	The	
slides	were	fixed	and	stained	with	a	modified	Wright‐Giemsa	stain	
(Tincion	 15,	 Biopur	 SRL,	 Rosario,	 Argentina),	 and	 a	 total	 of	 200	
cells	were	 counted	 for	 each	 sample	 by	 optical	microscopy.	 After	
lavage,	one	lung	was	extirpated	and	recollected	in	1	mL	of	Quick‐
Zol	reagent	(Kalium	Technologies)	for	RNA	extraction	following	the	
supplier's manual. The other lung was instilled with 10% buffered 
formalin,	removed	and	fixed	in	the	same	solution.	Following	paraf‐
fin	 embedding,	 tissue	 sections	 for	microscopy	were	 stained	with	
H&E	or	Periodic	acid‐Schiff	(PAS).	An	index	of	pathologic	changes	
in	H&E	slides	was	obtained	by	examining	20	consecutive	airways	
per	 slide	at	400×	magnification	and	 scoring	 the	 inflammatory	 in‐
filtrates	around	the	airways	and	vessels	for	severity	(0,	normal;	1,	
≤3	cells	diameter	thick;	2,	4	to	10	cells	diameter	thick;	3,	≥10	cells	
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diameter	 thick).	The	 Inflammatory	 Index	was	calculated	by	divid‐
ing the sum of the airway scores from each lung by the number 
of	airways	examined.	A	histological	goblet	cell	score	was	obtained	
in	PAS‐stained	lung	sections	by	examining	20	consecutive	airways	
per	 slide	at	400×	magnification	and	categorized	according	 to	 the	
abundance	of	PAS‐positive	goblets	(0,	<5%	goblet	cells;	1,	5	to	25%;	
2,	26	to	50%;	3,	51	to	75%;	4,	>75%).	The	Mucus	Index	was	calcu‐
lated by dividing the sum of the airway scores from each lung by the 
number	of	airways	examined	for	the	histological	goblet	cell	score.33














2.9 | RNA isolation & CDNA synthesis
Total	 cellular	 RNA	 was	 extracted	 using	 the	 Quick‐Zol	 reagent	
(Kalium	 Technologies,	 Buenos	 Aires,	 Argentina)	 following	 the	
supplier's	manual.	Total	RNA	was	dissolved	 in	RNase	 free	water,	
denatured	 for	 5	 minutes	 at	 65°C	 and	 RNA	 was	 quantified	 by	
spectrophotometric	 OD260	 measurement	 using	 the	 Bioanalyzer	
(Agilent	 Technologies,	 Palo	 Alto,	 CA,	 USA).	 RNA	 samples	 were	
stored	 at	 −80°C	 until	 further	 use.	 One	microgram	 of	 total	 RNA	




(Invitrogen,	 Thermo	 Fisher	 Scientific).	 Finally,	 they	were	 reverse	
transcribed	using	the	M‐MLV	Reverse	Transcriptase	according	to	
the	manufacturer's	 instructions	 (Promega	Biosciences	 Inc.).	From	
each	DNase	I‐treated	RNA	sample,	a	nonreverse	transcribed	(‐RT)	
sample was similarly generated (reverse transcriptase was replaced 
with	water).	cDNA	as	well	as	‐RT	samples	were	kept	at	−20°C.
2.10 | Quantitative polymerase chain reaction 
(QPCR)
Forward and reverse primer pairs were generated using the 
primer3Input online software (https ://prime r3plus.com/prime 
r3web/	prime	r3web_input.htm)	 and	 designs	 were	 based	 on	
publicly	 available	 mouse	 mRNA	 sequences.	 Primers	 were	 de‐
signed	 to	 have	 approximately	 50%	 G/C	 content	 and	 to	 generate	
75‐150‐bp	amplicons.	Primer	pair	specificity	against	target	sequence	
was	 checked	 in	 the	 NCBI	 Genbank	 database	 using	 Primer‐BLAST	
(http://www.ncbi.nlm.nih.gov/).	 The	 sequences	 of	 the	 primers	 used	
to	 detect	 ArgI,	 IL‐4,	 IL‐5,	 and	 Muc5AC	 were	 designed	 by	 us	 and	
were	 as	 follows:	 ArgI	 forward	 5’‐	 CGTGTACATTGGCTTGCGAG	
‐3’;	 ArgI	 reverse	 5’‐	 GCCAATCCCCAGCTTGTCTA	 ‐3’;	 IL‐4	
forward	 5’‐	 ATGGATGTGCCAAACGTCCT	 ‐3’;	 IL‐4	 re‐
verse	 5’‐	 AAGCACCTTGGAAGCCCTAC	 ‐3’;	 IL‐5	 for‐
ward	 5’‐	 AGGCTTTGTGCATGTTACCAAC	 ‐3’;	 Muc5AC	
forward	 5’‐	 GCAACTCCACCACCCCTACA	 ‐3’;	 Muc5AC	 reverse	
5’‐	CCTTGCTTGAGGCCCCTGA	‐3’.	Specific	mRNA	levels	were	nor‐
malized	 to	 CiclophylinA	 gene	 expression	 as	 recommended35 using 
the	 following	primers	 also	designed	by	us:	CiclophylinA	 forward	5’‐	
AGCACTGGAGAGAAAGGATTTG	 ‐3’;	 CiclophylinA	 reverse	 5’‐	 CCA	




qPCR	Mix	 Plus	 (Solis	 Biodyne,	 Tartu,	 Estonia).	 PCR	 reactions	 were	
performed in a total volume of 15 μL	containing	3	μL	of	HOT	FIREPol	
EvaGreen	 qPCR	 Mix	 Plus,	 1.5	 μL	 of	 a	 10‐fold	 diluted	 cDNA	 and	





thermocycling,	 determining	 dissociation	 of	 the	 PCR	 products	 from	
65°C	to	95°C	for	15	seconds.	Finally,	a	cooling	step	was	set	for	20	sec‐
onds	at	40°C.
To	 estimate	 the	 efficiency	 of	 the	 amplification	 reaction,	 serial	
half	logarithm	unit	dilutions	of	cDNA	were	used	and	standard	curves	
were generated. The linear slope of the standard curve for each 
primer	pair	was	estimated	using	GraphPad	Prism	6	software	and	the	
efficiency	was	calculated	based	on	this	following	formula	(1).
Additionally,	 the	 ‐RT	 samples	 and	 a	 water	 template	 were	 in‐
cluded	in	the	analysis	to	confirm	the	absence	of	any	residual	DNA	
or	 contamination.	 All	 cDNA	 samples	 were	 analyzed	 in	 triplicates.	
Finally,	the	following	formula	(2)	was	used	to	calculate	the	fold	 in‐
duction	of	gene	expression.
2.11 | Compliance with design and statistical 
analysis requirements
All	 animal	 groups	have	n	=	5.	 Samples	obtained	 from	each	animal	
were	measured	 three	 times	 to	 test	 precision.	 Randomization	 was	





Efficiency of target gene
Δcp target (control−experimental group)
Efficiency of reference gene
Δcp reference (control−experimental group)
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collect	and	process	data,	with	analysis	performed	by	 investigators	
blinded to the treatment groups.
The data and statistical analysis comply with the recommen‐
dations	 on	 experimental	 design	 and	 analysis	 in	 pharmacology.36 
Graphs	 and	 statistical	 analysis	 were	 performed	 using	 GraphPad	
Prism	 6.0	 (GraphPad	 Software	 for	 Science).	 Data	 are	 presented	
as	mean	±	standard	deviation	 (SD).	For	multigroup	comparisons,	 a	
one‐way	ANOVA	test	with	a	Tukey's	posttest	was	performed	using	
the same software package. No statistical differences between vari‐
ances	were	observed	along	the	whole	work	according	to	the	Brown‐
Forsythe test. Post hoc tests were run only if an overall statistically 
significant difference between the means were obtained. Statistical 
significance was accepted when P	<	.05.
3  | RESULTS
3.1 | AZE enhances DEX response in vitro
We	 first	 validated	 that	 AZE	 had	 similar	 effect	 on	 DEX‐induced	
GR	 transcriptional	 activity	 in	 vitro, as previously reported for 
the antihistamines mepyramine and triprolidine.4	HEK293T	 cells	
were cotransfected with a luciferase encoding plasmid under the 
control	 of	 a	 synthetic	 promoter	 regulated	by	 the	GR	 (TAT3‐Luc)	
in	 combination	with	 plasmids	 encoding	 for	 GR	 and	H1 receptor. 
In	this	system	we	found	that,	while	10‐μmol/L	AZE	alone	had	no	
effect,	 pretreatment	 with	 10‐μmol/L	 AZE	 enhanced	 0.1	 and	 1‐
nmol/L	 DEX‐induced	 luciferase	 activity	 by	 approximately	 2‐fold	
(1331	±	133	vs	2692	±	348	and	2784	±	360	vs	4842	±	483,	 re‐
spectively)	 (Figure	 1A).	 To	 evaluate	 if	 there	 was	 a	 potentiation	
of	GR	 transrepression,	we	used	 the	 same	cell	 system	but	with	a	
different luciferase reporter. Cells were cotransfected with an 
IL‐6	 promoter‐driven	 luciferase	 encoding	 plasmid,	 whose	 activ‐
ity	 was	 induced	 pretreating	 the	 cells	 with	 2000	 IU/mL	 TNF‐α. 
Pretreatment	with	 10‐μmol/L	 AZE	 potentiated	DEX‐induced	 re‐
pression	of	the	IL‐6	promoter	inducing	a	left	shift	in	the	dose‐re‐
sponse	curve	changing	 the	pEC50	 from	9.02	±	0.2	 to	9.45	±	0.2	
(Figure	1B).








mg/kg	DEX	and	0.5‐mg/kg	AZE	 for	 IgE	and	 IgG1.	Remarkably,	none	
of	the	treatments	had	an	effect	by	themselves,	suggesting	a	higher	ef‐
fectivity	of	 the	cotreatment	 (Figure	2A,	2,	and	2).	 In	 this	 regard,	 it	 is	
worth	mention	that	differently	from	what	was	previously	reported,	the	
optimal	dose	of	DEX	did	not	significantly	reduced	IgE	levels.
3.3 | AZE and DEX cotreatment reduces 
eosinophilia in BAL
Accumulation	of	eosinophils	in	alveoli	is	a	hallmark	of	allergic	asthma	
and inflammation of the airways mediated by these cells is charac‐
teristic	of	the	experimental	model	used	herein.32,33 We performed a 
differential	count	BAL	cells	of	the	different	animals.	Analysis	showed	
that	there	is	a	rise	in	eosinophilia	in	OVA‐sensitized	mice,	confirming	
the induction of a pathological condition. Treatment with 1 mg/kg of 
DEX	reduced	it	to	almost	the	half	(from	62.3	±	5.8%	to	36.5	±	6.4%),	
while	 the	 administration	of	0.1‐mg/kg	DEX	or	AZE	alone	 resulted	
ineffective.	On	 the	other	hand,	cotreatment	with	0.5	 ‐mg/kg	AZE	
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of	AZE	to	a	low	dose	of	DEX	could	allow	reaching	a	greater	or	equal	
therapeutic	efficacy	as	that	of	higher	DEX	dose.
3.4 | AZE and DEX cotreatment improves lung 
histopathology
Aerosol	exposure	of	the	animals	to	the	allergen	OVA	produces	an	
allergic‐inflammatory	 reaction	 of	 the	 airways	 that	 is	 reflected	 in	
pathophysiological changes in lung tissue which is typical of the 
clinical phenotype of all types of asthma. To evaluate whether sup‐
pressed	BAL	eosinophilia	correlated	with	reduced	lung	pathology,	
we	 analyzed	H&E	 and	PAS	 lung‐stained	 sections	 of	 the	 different	
animals.	Mice	sensitized	with	OVA	(Figure	4A)	showed	typical	path‐




showed a small inflammatory infiltrate with reduced mucus produc‐
tion	and	no	goblet	hyperplasia	(Figure	4E)	while	no	significant	dif‐




showed reduced peribronchial and perivascular infiltration and 
mucus	production	(Figure	4D)	which	resulted	significantly	different	
from	the	treatments	alone.	Results	of	semiquantitative	histological	
scoring	showed	 that	1‐mg/kg	DEX	 induced	a	70%	of	 suppression	
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of	the	allergic	infiltration	(from	100.0	±	5.3%	to	30.7	±	6.4%),	while	
the	 cotreatment	 with	 a	 0.1‐mg/kg	 DEX	 and	 0.5‐mg/kg	 AZE	 re‐
duced	 it	by	30%	 (from	100.0	±	5.3%	to	71.2	±	6.3%).	Treatments	
with the individual drugs did not significantly reduce this parameter 
(Figure	4G).	Similar	observations	were	made	for	PAS‐stained	lungs	
sections in which the histological goblet cell score was reduced by 
64%	in	animals	who	received	a	1‐mg/kg	DEX	(from	100.0	±	12.2%	
to	35.9	±	11.8%);	by	40%	 in	 those	who	received	 the	cotreatment	
of	 0.1‐mg/kg	 DEX	 and	 0.5‐mg/kg	 AZE	 (from	 100.0	 ±	 5.3%	 to	
59.4	 ±	 8.6%);	 while	 no	 significant	 differences	 were	 observed	 in	
animals who received the treatments alone with respect to vehicle 
(Figure	4H),	supporting	the	qualitative	changes	described	above.
3.5 | AZE and DEX cotreatment reduces the 
expression of asthma‐inflammatory genes
One key feature of this model is the development of an anti‐
gen‐specific	 Th2	 immune	 response.	 Th2	 cells	 are	 characterized	
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by	 the	 release	of	 specific	 cytokines,	 notably	 interleukin	4	 (IL‐4)	
and	interleukin	5	(IL‐5)	that	promotes	airway	inflammation	rich	in	
eosinophils,	which	are	considered	 responsible	 for	 the	asthmatic	
response	 (Mullane	et	al,	2014).	Accordingly,	we	decided	 to	ana‐
lyze	the	expression	of	these	cytokines	 in	 lung	samples	obtained	













model	 of	 experimental	 asthma.	 Specifically,	we	have	 shown	a	 sig‐
nificant	decrease	 in	eosinophils	 in	BAL	 lavage,	fewer	peribronchial	
and	perivascular	infiltrates	and	mucin‐producing	cells.	In	addition,	a	
diminished	level	of	OVA‐specific	IgE	and	IgG1	was	detected.
GCs	 are	 among	 the	 most	 effective	 therapy	 to	 treat	 asthma	
and are usually the therapeutic choice for adults and children 
with	severe	asthma.	International	guidelines	such	as	GINA	(Global	
Initiative	 for	 Asthma)	 and	 NAEPP	 (National	 Asthma	 Education	
and	Prevention)	 recommend	GCs	 inhalation	as	 therapy	of	choice	
to	control	 long‐term	persistent	asthma,	due	to	 its	anti‐inflamma‐
tory effects.31,37 Suppression of proinflammatory genes reflect 
the molecular effects that result in an improvement of symptoms 
and	pulmonary	 function,	as	well	as	a	 reduction	of	exacerbations	
and airways hyper response.38	 However,	 there	 are	 at	 least	 two	
major	issues	concerning	GCs’	therapy.	On	the	one	hand,	there	are	
GCs‐resistant	 patient	 populations	which	may	 represent	 5%‐10%	
of the total.39	On	 the	other	hand,	chronic	 treatment	with	a	high	
dose	of	GCs	could	lead	to	the	development	of	important	adverse	
effects.40‐43
Concerning	 the	 improvement	 of	 GCs’	 beneficial/adverse	
effects	 ratio,	 different	 strategies	 have	 been	 investigated,	 from	
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chemical	 optimization	 of	 physiological	 corticoids	 to	 the	 devel‐
opment	 of	 Selective	 Glucocorticoid	 Receptor	 Agonists	 and	
Modulators	 (SEGRAs	 and	 SEGRMs).	 Complementary	 thera‐
pies	 are	an	alternative	 to	 control	 adverse	effects,	 in	which	 the	
addition of a different drug allows to reduce the dose of the 
corticoid. β2‐adrenoceptor	 agonists,	 theophylline,	 and	 antileu‐
kotrienes	are	widely	used	with	this	purpose,	being	the	first	ones,	
the most effective.9 Combination of β2‐agonists	and	corticoids	is	
supported by scientific rationale. There are complementary ef‐
fects on the physiopathology of asthma and synergic or at least 
additives effects at the molecular level. It has been reported that 
β2‐agonists	 increase	 GC‐induced	 GR	 nuclear	 localization	 and	
transcriptional activity.44
The efficacy of antihistamines for the treatment of asthma has 
been intensively studied over the last 50 years. Since mast cells 
were	identified	as	key	players	in	allergic	asthma	development,	first	
and second generation of antihistamines were evaluated. Due to 
its proinflammatory effects histamine has been related to asthma 
development and abundant preclinical observations support this 
relationship.12	However,	 antihistamines	 have	 failed	 to	 be	 clinically	
effective for the management of asthma due to limited efficacy ob‐
served in several studies.13
We have previously reported a crosstalk mechanism between 
H1	receptor	and	GR‐mediated	signaling	pathways.	This	mechanism	
involves	 a	 dual	 regulation	 of	GR	 activity	 by	 the	H1R:	 a	 potentia‐
tion	 mediated	 by	 G‐protein	 βγ subunits and a parallel inhibitory 
effect	mediated	by	a	Gαq‐PLC	pathway.	Activation	of	the	H1 recep‐
tor by its full agonists resulted in a composite potentiating effect. 
Intriguingly,	 inactivation	of	 the	Gαq‐PLC	pathway	by	H1 receptor 
inverse	 agonists	 (ie,	mepyramine	and	 triprolidine)	 resulted	also	 in	
a	potentiation	of	GR	activity.4 This was observed in heterologous 
expression	 systems,	 through	 gene‐reporter	 assays	 and	 measur‐
ing	 the	 expression	 of	 endogenous	 inflammatory‐related	 genes	 in	
physio‐pathological	 cell	 models.4 Now we show that another in‐
verse	agonist,	AZE	can	also	potentiate	DEX‐induced	GR	activity	in	
vitro	(Figure	1).	It	can	be	inferred	that	if	the	molecular	mechanisms	
underpinning this pharmacological potentiation observed in vitro 
would	also	exist	in	vivo	in	a	clinically	relevant	target	organ,	cotreat‐
ment	 with	 DEX	 and	 AZE	 could	 present	 a	 therapeutic	 advantage	










redistribution,	 muscular	 weakness	 and	 atrophy,	 insulin	 resistance,	
glucose intolerance and even diabetes.46	Given	that	anti‐inflamma‐
tory	and	adverse	effects	share	the	same	molecular	mechanisms	and,	
as	 we	 described,	 antihistamines	 could	 enhance	 DEX‐induced	 GR	
activity	both	for	gene	transactivation	and	transrepression,	it	should	
be	critical	to	address	the	potential	modulation	of	GR	adverse	effects	
by antihistamines in order to assure their complete safety. Induction 
of	adverse	effects	by	long‐term	use	of	corticoids	at	high	doses	might	
be	reduced	by	diminishing	corticoid	dosage.	However,	corticoids’	ad‐
verse effects could be also enhanced by antihistamines.
There are some limitations to this study that warrant discussion. 
First,	it	remains	to	be	confirmed	whether	the	diminished	lung	allergy	
inflammation also correlates with lower airway hyperresponsiveness 
observed in asthma. Other shortcomings are related to the asthma 
protocol. The murine model used herein involves systemic sensiti‐
zation	with	OVA	as	allergen	followed	by	an	aerosol	challenge.	This	
model reproduces many key features of clinical asthma such as ele‐
vated	levels	of	allergen‐specific	IgE,	airway	inflammation,	goblet	cell	
hyperplasia,	 epithelial	 hypertrophy,	 and	 airways	 hyperresponse47 
and represents the most used preclinical model that resulted very 
useful to elucidate different aspects of the pathology of the disease 
and	to	search	for	new	therapeutic	treatments.	However,	it	is	an	acute	
model whose suitability is limited due to minimal airway remodeling 
and the transient nature of the bronchial hyperreactivity and the eo‐
sinophilic inflammation that resolves within a few weeks.32 This set‐
tles	the	need	of	evaluating	our	hypothesis	in	a	chronic	model,	which	
reproduces	better	the	changes	observed	in	patients,48 although they 
are still limited and there has not yet been widely adopted a single 
model.	It	is	clear	that	although	murine	models	do	not	exactly	repro‐
duce	the	pathophysiology	of	asthma,	they	have	proved	to	be	a	valu‐
able tool for investigation.32
In	conclusion,	our	results	contribute	to	the	ongoing	reevalua‐
tion	of	the	use	of	antihistamines	as	add‐on	drugs	in	GCs‐mediated	
anti‐inflammatory	 therapies.	 Based	 on	 the	 described	 crosstalk	
between	 H1	 receptor	 signaling	 and	 GR	 activity,	 antihistamines	
could	be	repositioned	as	adjuvants	for	GC‐based	therapies	to	di‐
minish their adverse effects.45 Considering the widespread use 
of	both	 types	of	drugs,	 the	 repositioning	of	 antihistamines	may	
make	available	new	and	safer	therapeutic	strategies,	offering	new	
options to improve the management of the symptoms in patients 
with	 asthma	 and	other	 related	 inflammation‐related	 respiratory	
conditions.
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